Advanced search
Publication Cover
Journal of Medical Economics Volume 25, 2022 - Issue 1
Submit an article Journal homepage
4,004
Views
6
CrossRef citations to date
0
Altmetric
Nephrology

Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome

Adrian R. Levya Department of Community Health and Epidemiology, Dalhousie University, Halifax, NS, CanadaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8966-0966
ORCID Icon,
Peter Chenb Alexion, AstraZeneca Rare Disease, Boston, MA, USAORCID Iconhttps://orcid.org/0000-0003-2015-9943
ORCID Icon,
Karissa Johnstonc Broadstreet Health Economics and Outcomes Research, Vancouver, BC, CanadaORCID Iconhttps://orcid.org/0000-0003-4570-9972
ORCID Icon,
Yan Wangb Alexion, AstraZeneca Rare Disease, Boston, MA, USAORCID Iconhttps://orcid.org/0000-0001-9578-4781
ORCID Icon,
Evan Popoffc Broadstreet Health Economics and Outcomes Research, Vancouver, BC, CanadaORCID Iconhttps://orcid.org/0000-0002-3233-3147
ORCID Icon &
Ioannis Tomazosb Alexion, AstraZeneca Rare Disease, Boston, MA, USAORCID Iconhttps://orcid.org/0000-0003-0290-4583
ORCID Icon
Pages 249-259 | Received 30 Sep 2021, Accepted 07 Jan 2022, Published online: 17 Feb 2022

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Gema Ariceta. (2023) Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Expert Review of Clinical Pharmacology 16:5, pages 401-410.
Read now
Amelia Stennett, Kallie Friston, Claire L. Harris, Adam J. M. Wollman, Agnieszka K. Bronowska & Katrina S. Madden. (2023) The case for complement component 5 as a target in neurodegenerative disease. Expert Opinion on Therapeutic Targets 27:2, pages 97-109.
Read now

Articles from other publishers (4)

Kamran Shahid & Shahid Qayyum. (2023) Eculizumab Versus Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome: A Systematic Review. Cureus.
Crossref
Dervla M. Connaughton, Pratibha Bhai, Paul Isenring, Mohammed Mahdi, Bekim Sadikovic & Laila C. Schenkel. (2023) Genotypic analysis of a large cohort of patients with suspected atypical hemolytic uremic syndrome. Journal of Molecular Medicine 101:8, pages 1029-1040.
Crossref
Farhana BegumNida KhanStephanie Boisclair, Deepa A. MalieckalDavid Chitty. (2023) Complement Inhibitors in the Management of Complement-Mediated Hemolytic Uremic Syndrome and Paroxysmal Nocturnal Hemoglobinuria. American Journal of Therapeutics 30:3, pages e209-e219.
Crossref
Bradley P. Dixon & Ashley Sabus. (2022) Ravulizumab 100 mg/mL formulation reduces infusion time and frequency, improving the patient and caregiver experience in the treatment of atypical haemolytic uraemic syndrome. Journal of Clinical Pharmacy and Therapeutics 47:7, pages 1081-1087.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.